Novo's (NOVOB DC) Ozempic for Australians is expected to fall from about AUD 300 a month for private patients to a small fraction after Australian patents expire in late 2029 and 2031, according to WA Today
Context
The potential expiration of patents for Novo's Ozempic in Australia could significantly reduce patient costs, impacting the firm's pricing power and market share. This scenario may shape investor sentiment towards Novo Nordisk, with possible read-throughs on profitability and competitive dynamics in the diabetes treatment market. Traders should watch for shifts in valuation as these regulatory changes approach.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#AUSTRALIA#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#EUROPEAN EQUITIES